Trial intelligence / Profile preview

LIBRETTO-431 phase 3 trial of selpercatinib versus pemetrexed-platinum chemotherapy with or without pembrolizumab in RET fusion-positive advanced non-small cell lung cancer

CTR20192731Phase 3Active

Sponsor

Eli Lilly and Company

Start

Dec 2020

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1